|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that G-CSF/GM-CSF use is well tolerated and suggest that G-CSF can sometimes be safely used to reduce the duration of neutropenia associated with clozapine use.
|
28437295 |
2017 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with G-CSF could eventually be stopped, and the neutropenia, ultimately transient in nature, completely resolved.
|
30633375 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
G-CSF is a leukocyte stimulating molecule which is commonly used in cancer patients to prevent or reduce neutropenia.
|
29283548 |
2018 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report a case of localized pustular eruption on the face in a patient with Hodgkin lymphoma treated with granulocyte colony-stimulating factor for the development of chemotherapy-induced neutropenia.
|
27845511 |
2018 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conducted this review of neutropenia in BTHS to aid in the diagnosis of this disease, and to improve understanding of both the consequences of neutropenia and the benefits of treatment with granulocyte colony-stimulating factor (G-CSF).
|
30451719 |
2019 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with WHIM syndrome are often treated with granulocyte colony-stimulating factor (G-CSF), which can increase neutrophil counts but does not affect cytopenias other than neutropenia.
|
30625055 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Twenty-eight (19%) patients were treated with peg-filgrastim as primary prophylaxis, while 74 (64%) received filgrastim "on demand" due to neutropenia.
|
31152919 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study shows the increase or decrease in monocyte count is a significant potential indicator to predict the occurrence of neutropenia, and it is also a predictor to guide the next monitoring time of neutrophil count and the treatment of granulocyte-colony stimulating factor.
|
30249869 |
2018 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Severe infectious complications were avoided by early administration of G-CSF for leukocytopenia and by continuous oral administration of antibiotics.
|
11475155 |
2001 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Filgrastim, a granulocyte-colony stimulating factor, is used to treat patients with neutropenia, including neutropenic fever.
|
30122896 |
2018 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
|
30043207 |
2018 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, myelokathexis associated with abnormally high neutrophil CXCR4 expression may contribute to neutropenia in G6PC3 deficiency and responds well to granulocyte colony-stimulating factor.
|
20616219 |
2010 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte-colony stimulating factor (G-CSF, 10 μg/kg/day, subcutaneously) was administered from the onset of neutropenia to the final day of collection.
|
30642286 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
|
29091995 |
2018 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (GCSF) is an option to treat leukopenia in lung transplant recipients.
|
28314052 |
2017 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
G4 neutropenia occurred in 11 patients (28 of 33 cycles) in the filgrastim arm and 9 patients (18 of 33 cycles) in the pegfilgrastim arm (P = 0.476).
|
31728715 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The clinical concomitant is a severe, G-CSF-responsive neutropenia in addition to oculocutaneous albinism and platelet storage pool deficiency.
|
11809908 |
2002 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients received subcutaneous filgrastim as part of the prophylaxis regimen for neutropenia.
|
31623097 |
2019 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony stimulating factor (GCSF) is clinically used as a treatment for congenital and acquired neutropenia.
|
22427476 |
2012 |
|
Leukopenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Febrile neutropenia requiring hospitalization was defined as hospitalization within 14 days after G-CSF use with (a) diagnosis of infection and/or neutropenia (broad definition) or (b) infection and neutropenia diagnoses (narrow definition).
|
29172983 |
2017 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The addition of G-CSF to attenuate neutropenia did not improve tolerability.
|
30128950 |
2018 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy delay due to neutropenia was higher in patients who received granulocyte-colony stimulating factor on day 1.
|
31042138 |
2020 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Biosimilars of the granulocyte colony stimulating factor (G-CSF) filgrastim were approved by the European Medicines Agency (EMA) for registered indications of the originator G-CSF, including prevention and treatment of neutropenia, as well as mobilization of peripheral blood stem cells in 2008.
|
27509033 |
2016 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This qualified model simulates the time course of ANC in the absence or presence of chemotherapy and predicts nadir, time to nadir and time of recovery from different grades of neutropenia upon treatment with filgrastim and pegfilgrastim.
|
29318653 |
2018 |
|
Leukopenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Synthesis and characterization of heparosan-granulocyte-colony stimulating factor conjugates: a natural sugar-based drug delivery system to treat neutropenia.
|
28973394 |
2017 |